Mersana To Focus Fully On Anti-Cancer ADCs With $27M Recapitalization
This article was originally published in The Pink Sheet Daily
Executive Summary
Nearly ready to out-license its remaining small molecule drug conjugate candidate, Mersana will focus exclusively on developing Fleximer-based antibody-drug conjugates through collaborations with Endo and future partners.
You may also be interested in...
Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.
Mersana Teams With Teva To Develop Polymer Conjugate Cancer Drug
Linking fumagillin analogue with polymer should prevent CNS toxicities seen with previous fumagillin candidates.
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.